BIOCAD is an international, vertically integrated biotechnology company. It excels at full-cycle drug discovery and development, as well as commercial-scale manufacturing of therapeutic proteins for the treatment of various types of cancer and autoimmune disorders. This year, BIOCAD launched its first two drug products based on original monoclonal antibodies, netakimab (anti-IL17) and prolgo...

  • RU
  • 2015
    On CPHI since
Contact info
  • Svyazi 34-A , Strelna, 198515, Saint-Petrsburg, Russian Federation

Products from BIOCAD (3)

  • Netakimab

    Product Netakimab

    ONetakimab – an original humanized monoclonal antibody against IL-17. Approved in Russia for plaque psoriasis. Pending approval for ankylosing spondylitis. BIOCAD will also launch an international Phase III clinical trial with the aim of approval in EU.
  • Prolgolimab

    Product Prolgolimab

    Prolgolimab is the original fully human anti-PD1 monoclonal antibody for the treatment of advanced melanoma, advanced NSCLC and metastatic cervical cancer. Pending approval in Russia for melanoma in 2019. For marketing authorization in EU BIOCAD is starting Phase III clinical trials.
  • Rituximab

    Product Rituximab

    Rituximab biosimilar, chimeric monoclonal antibody which specifically binds to the transmembrane antigen CD20. Indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)...